Cutaneous Actinomycosis Associated with Anti-TNF-Alpha Therapy: Report of Two Cases
| Autor: | G. Lamblin, C. Pariset, D. Jullien, A.L. Breton |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Antibiotics Dermatology Actinomycosis Receptors Tumor Necrosis Factor Etanercept Arthritis Rheumatoid Risk Factors Psoriasis medicine Humans Tumor Necrosis Factor-alpha business.industry Cutaneous actinomycosis Antibodies Monoclonal Surgical wound Middle Aged medicine.disease Infliximab Anti-Bacterial Agents Treatment Outcome Antirheumatic Agents Immunoglobulin G Rheumatoid arthritis Female Dermatologic Agents business medicine.drug |
| Zdroj: | Dermatology. 228:112-114 |
| ISSN: | 1421-9832 1018-8665 |
| DOI: | 10.1159/000357522 |
| Popis: | Increased susceptibility to infections is among the main safety concerns raised by anti-TNF-α agents. We describe two cases of cutaneous actinomycosis in patients undergoing anti-TNF-α therapy: a 49-year-old female treated with etanercept for rheumatoid arthritis and a 57-year-old female treated with infliximab for psoriasis. Both patients had discharge with the intermittent presence of sulfur granules occurring at the site of previous surgical wounds. Bacteriological culture demonstrated Actinomyces. Since in both cases laboratory findings and medical imaging ruled out visceral actinomycosis, oral antibiotics were introduced without discontinuing anti-TNF-α. The first patient did not relapse after 2 years. The second one did and received a second course of antibiotics combined with transient interruption of the anti-TNF-α therapy. The risk of developing actinomycosis is reported to be similar in immunocompetent and immunocompromised patients, however cases of cutaneous actinomycosis occurring during anti-TNF-α therapy need to be recognized and may be under-reported. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|